



Contact @ Bicoll GmbH
Dr. Nicole Feling
+49 89 820 725 64
nicole.feling@bicoll-group.com

FOR IMMEDIATE RELEASE

BICOLL GMBH, MUNICH/GERMANY MAKES APPOINTMENTS TO ITS ADVISORY BOARD

Munich, Germany – April 8th, 2003 – Bicoll GmbH, Munich announced today the four members of the company's Advisory Board. With Thorsten Bach, Ph.D., Hardy Debuch, Ph.D., K. Peter C. Vollhardt, Ph.D., and Sina Afra, MBA, the Bicoll-Group will strengthen the company's sustainable strategy for modern drug design using its proprietary technology platform for natural product chemistry, combinatorial chemistry and screening techniques.

"The Bicoll-Group looks forward to working with each of these qualified individuals, who gained strong records in their fields of interest," said Dr. Kai Lamottke, managing director of Bicoll GmbH and board member of Bicoll Biotechnology (Shanghai) Co. Ltd.. "As we are currently successfully implementing our unique business model on the global market, our advisory board will certainly contribute with its high expertise to a profitable business growth in the international perspective."

Thorsten Bach is Professor of Organic Chemistry at the Technical University, Munich. His special interest is dedicated to the total synthesis of bioactive natural products utilizing photo- and organometallic chemistry. In cooperation with industrial and academic partners the research group of Thorsten Bach seeks to find new leads for modern drug research and to elucidate structure-activity-relations. In 2001 Thorsten Bach was awarded the Astra Zeneca Research Award.

Professor Bach gained his thorough experience in organic chemistry with G.A. Olah (1987-1988), M.T. Reetz (1988-1991), D.A. Evans (1991-1992) and D. Hoppe (1992-1996).

So far Professor Bach authored more than 85 publications and serves as Editor for the journal *Synthesis*.

Hardy Debuch runs his own international consultancy for the pharmaceutical industry market, DHD Unternehmensberatung AG. His extensive experience has been gained in more than 30 years assuming leading positions in pharmaceutical research and marketing with E. Merck, Darmstadt/Germany, Röhm Pharma, Germany and Schwarz Pharma, Germany. In his role as chair and CEO of Schwarz Pharma's U.S. and Italian divisions, Hardy Debuch was leading Schwarz Pharma from a German-oriented company to a global market player.

K. Peter C. Vollhardt is Professor in the Department of Chemistry, University of California at Berkeley, Senior Principal Investigator at the Chemical Science Division, Lawrence Berkeley National Laboratory, and Assistant Dean to the College of Chemistry. As one of the world's foremost organic chemists, he was awarded the Adolf Windaus Medal of the German Chemical Society (1983), a Humboldt Senior Scientist Award (1985 and 1992), the ACS Award in Organometallic Chemistry (1987), the Otto Bayer Prize 1990, the ACS Arthur C. Cope Scholar Award 1991, a Japan Society for Promotion of Science Award 1995, the Stiftung Buchkunst Prize (Germany) 1996, the ACS Edward Leete Award 1999, and the Medal of the University Aix-Marseille (2000). Professor Vollhardt has more than 30 years of experience in the application of transition metals to enable the synthesis of complex natural and unnatural products. His outstanding scientific work led to over 265 scientific papers. In addition he authored the standard college textbook on organic chemistry and serves as Chief Editor for the journal *Synlett*.

Sina Afra has more than 10 years experience in the consulting business. He is Senior Manager for the Frankfurt office of Bearing Point (former KPMG) where he belongs to the department World Class Finance. Sina Afra is specialized in the area of Value Based Management, Planning and Cost Accounting. Beside these, he has expertise in conducting international market and valuation studies. Sina Afra also gained experience in competition analysis for diverse leading international chemicals companies and edited the Value Based Management Study "*Concepts of Shareholder Value- an analysis of the DAX 100 companies*".

About Bicoll

The Bicoll group is an international biopharmaceutical enterprise with a head office in Munich, Germany, and its research and development location in Shanghai, P.R. China.

The company provides an innovative, fast and flexible approach to modern drug research. Bicoll provides optimized, high-quality small molecule libraries (BILOBAC N) for drug discovery cooperations with companies of the biopharmaceutical industry. The submitted libraries are specially designed for the target protein of the partner's indication field to provide highest success rate. The starting material is generated through Bicoll's access to Asian plant resources.

Bicoll's two core technologies BIFRAC N and BIPRESELECT enable the company to accelerate the development process of new drug candidates. BIFRAC N is an isolation and separation system to detect biologically active compounds. By applying the BIPRESELECT process, the company identifies selected ADME criteria. Thus Bicoll is able to sort out non-successful drug candidates, which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third.

Currently, Bicoll is initiating its own in-house drug development projects, one of which is in the area of central nervous system disorders.